Caring Cross
Caring Cross is a 501(c)(3) nonprofit developing affordable CAR-T and stem cell gene therapies for cancer, HIV, and sickle cell disease, using technology transfer and decentralized point-of-care manufacturing to serve patients in low- and middle-income countries.
- Company typePrivate
- Founded2012
- HeadquartersGaithersburg, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Caring Cross does
Caring Cross is a 501(c)(3) nonprofit founded in 2012 and headquartered in Gaithersburg, Maryland, focused on developing and deploying affordable CAR-T cell immunotherapies and stem cell gene therapies for cancer, HIV, sickle cell disease, and beta-thalassemia. Its core technology portfolio includes a TriCAR-T cell therapy (with a CD19/CD20/CD22 targeting construct), an anti-HIV duoCAR-T therapy currently in Phase I/IIa clinical trials, an autologous stem cell gene therapy platform for sickle cell disease and beta-thalassemia, and a proprietary T-isopure reagent that simplifies cell therapy manufacturing. The organization also operates an AATM (Advanced Therapy Access Model) network that enables decentralized, point-of-care manufacturing of these therapies in low- and middle-income countries.
The company's business model is built on non-dilutive funding rather than commercial product sales. Revenue is sourced from US federal grants (NCI/NIH, NIST, NIIMBL, ARPA-H), philanthropic support (notably the Bill & Melinda Gates Foundation), technology transfer agreements with international partners (Fiocruz/Brazil), and corporate partnerships. A for-profit CDMO, Vector BioMed, was spun out to manufacture lentiviral vectors for third parties and generate earned revenue tied to the broader Caring Cross ecosystem. Caring Cross serves patients who lack access to high-cost cell and gene therapies, particularly in global health settings, while partnering with ministries of health, academic centers, and hospital networks to localize manufacturing.
Distribution is achieved through technology transfer rather than direct commercialization: international partners adopt the company's manufacturing protocols and reagents to produce therapies locally, supported by Caring Cross's training, quality systems, and process know-how. The model targets a 90%+ cost reduction versus centralized CDMO-produced CAR-T, intending to convert cell and gene therapies from luxury medical interventions into broadly accessible treatments across emerging markets.
Caring Cross firmographics
Firmographics- Name
- Caring Cross
- Legal name
- Caring Cross
- Website
- https://caringcross.org
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Caring Cross is a 501(c)(3) nonprofit developing affordable CAR-T and stem cell gene therapies for cancer, HIV, and sickle cell disease, using technology transfer and decentralized point-of-care manufacturing to serve patients in low- and middle-income countries.
- Ownership category
- akta.pro rank
Where Caring Cross is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Caring Cross business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Government Grants and Funding: Caring Cross receives grants from US Federal government (NCI/NIH, NIST, NIIMBL) supporting development of Lentiviral vector and AAV vector technologies, as well as standards development for characterization of critical materials used in advanced therapeutic products.
- Technology Transfer Agreements: Technology transfer partnerships with government health organizations (e.g., Fiocruz) where Caring Cross provides technology, materials, and training for manufacturing CAR-T cell therapies and lentiviral vectors in exchange for licensing fees and ongoing collaboration.
- Corporate Partnership Services: Vector BioMed, a for-profit Benefit Corporation spun out from Caring Cross, provides GMP lentiviral vector manufacturing services to the industry at approximately half the price of competitors, generating revenue that supports Caring Cross's mission.
- Donations and Charitable Contributions: As a 501(c)(3) non-profit, Caring Cross accepts donations to support its mission of translating plans into actionable steps to make curative approaches to SCD and HIV available in low and middle-income countries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Commercial CAR-T cell therapy pricing |
| Unit Pricing | Multi-year contract | Brazil public health system pricing through Fiocruz partnership |
| Unit Pricing | Multi-year contract | AACT Network Academic Medical Center pricing |
| Unit Pricing | Pay-as-you-go | Vector BioMed GMP Lentiviral Vectors |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels8 records
Caring Cross product offering
Product offeringCore offering
Caring Cross is a 501(c)(3) nonprofit that develops CAR-T cell therapies and stem cell gene therapies for leukemia, lymphoma, HIV, sickle cell disease, and beta-thalassemia. The organization creates enabling technologies, including the proprietary T-isopure reagent and novel lentiviral vector manufacturing processes, and transfers these to partner Academic Medical Centers, government health agencies, and hospitals globally to enable decentralized, point-of-care manufacturing that reduces therapy costs from over $350,000 to approximately $35,000 per dose.
Product overview
Caring Cross is a 501(c)(3) non-profit developing a portfolio of advanced cell and gene therapies alongside enabling technologies. The core therapeutic products include TriCAR-T cell immunotherapy for leukemia and lymphoma (targeting CD19/CD20/CD22), anti-HIV duoCAR-T cell therapy in clinical trials, and stem cell gene therapies for sickle cell disease and beta-thalassemia. The company also offers proprietary manufacturing reagents (T-isopure™) and has spun out Vector BioMed for GMP lentiviral vector manufacturing. These products are supported by the AATM Network platform enabling decentralized, point-of-care manufacturing at partner Academic Medical Centers worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- TriCAR-T Cell Immunotherapy Multi-targeted CAR-T cell therapy candidate designed to prevent relapse in leukemia and lymphoma patients by simultaneously targeting CD19, CD20, and CD22 surface proteins on cancer cells, addressing the approximately 50% relapse rate seen with single-target anti-CD19 CAR-T therapy.
- Anti-HIV duoCAR-T Cell Therapy CAR-T cell therapy candidate for HIV-1 infection designed to eliminate HIV-infected cells and protect CD4 T cells from HIV infection; in Phase I/IIa clinical trials at UCSF and UC Davis.
- Stem Cell Gene Therapy for Sickle Cell Disease and Beta-Thalassemia Autologous hematopoietic stem cell gene therapy candidates for sickle cell disease and beta-thalassemia using lentiviral vectors. Phase I/IIa clinical trial planned for 2025, with multi-center trials to follow.
- T-isopure Reagent Proprietary reagent that significantly simplifies and reduces the cost of CAR-T cell manufacturing process, increasing robustness and allowing manufacturing from whole blood or apheresis blood product.
- Vector BioMed GMP Lentiviral Vectors GMP-grade lentiviral vectors manufactured by Vector BioMed (spun out from Caring Cross) at approximately half the price of competitors; includes custom lentiviral vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors.
- Affordable Advanced Therapies Manufacturing (AATM) Network Global network of Academic Medical Centers collaborating with Caring Cross to enable point-of-care GMP manufacturing capabilities, accelerate research and clinical development, and improve patient access to affordable CAR-T and other advanced therapies.
Quantifiable outcome
- Three HIV trial participants achieved viral suppression lasting 48-92 weeks after single CAR-T infusion
- +5 more outcomes
Companies that use Caring Cross
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Caring Cross technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature6 records
Caring Cross partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered secondary and core.
- Nigeria Ministry of HealthsecondaryNigeria's government reaffirmed commitment to advancing health innovation through partnerships with Caring Cross, focusing on solutions such as CAR T-cell therapy to improve health outcomes. Initiative aims to leverage Nigeria's biodiversity and develop local medical solutions addressing diseases like sickle cell and blood cancers.
- Trenchant BioSystemssecondaryPartnership with Trenchant BioSystems and University of Massachusetts Chan Medical School to develop automated manufacturing platform for gene-modified HSC therapies targeting sickle cell disease and beta thalassemia. Leverages AutoCell platform with microbubble separation technology. Plans FDA INTERACT meeting Q1 2027 and Phase I/II trial later that year.
- BioCuriesecondaryBioCurie awarded up to $9.3 million from ARPA-H to develop AI platform for scalable gene therapy manufacturing. Caring Cross is part of consortium including St. Jude Children's Research Hospital, Center for Breakthrough Medicines, and University City Science Center. Platform aims to replace trial-and-error process development with computational modeling.
- Amrita Research Center Delhi and Amrita Vishwa VidyapeethamcoreStrategic partnership to develop and implement affordable, scalable cell and gene therapy solutions for underserved populations in India. Collaboration establishes decentralized therapeutic manufacturing and advances TriCAR-T cell therapies for Leukemia, Lymphoma, Sickle Cell Disease, Thalassemia, and various cancers.
- Burjeel HoldingscorePartnership to establish local manufacturing of CAR-T and stem cell gene therapies in MENA region, reducing treatment costs by up to 90%. Initial focus on leukemia and lymphoma with plans to expand to other treatments. GMP facility in Abu Dhabi to process up to 200 samples simultaneously, announced at Abu Dhabi Global Health Week.
- GermfreecorePartnership to enable place-of-care GMP manufacturing by combining Germfree's advanced mobile cleanroom technology with Caring Cross's manufacturing expertise and CGT products. Addresses limitations of CGTs being expensive, time-consuming to produce, and only available in affluent regions. Builds on three-year collaboration including Fiocruz pilot project.
- Fundação Oswaldo Cruz (Fiocruz)coreTechnology transfer agreement with Fiocruz and Brazilian Ministry of Health to develop, manufacture, and commercialize CAR-T cell therapies for Brazilian population and Latin America. Caring Cross provides technology, materials, and training to Bio-Manguinhos for CAR-T and lentiviral vector manufacturing. Treatment cost reduced to approximately $35,000 per dose (10% of US/Europe pricing).
- Vector BioMedcoreVector BioMed, founded as a for-profit Benefit Corporation, operates as a leading viral vector manufacturing CDMO. Established on novel lentiviral vector technology developed at Caring Cross. Offers GMP lentiviral vectors at half the price of competitors, custom vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors for in vivo gene therapy. Manufacturing facilities in Gaithersburg, Maryland.
- CytivasecondaryCollaboration provides technologies and solutions supporting Caring Cross's mission to enable affordability and accessibility of CAR-T cell therapies. Cytiva provides equipment including Sepax C-Pro, VIA Thaw, and VIA Freeze instruments to streamline CAR-T manufacturing processes, reduce processing times, and minimize contamination risks.
- Bill and Melinda Gates Foundation (BMGF)coreCaring Cross working with BMGF to develop lentiviral vector manufacturing processes to decrease cost of gene therapy delivery. Project focuses on developing lentiviral vectors that can be used directly as injectable medicines for treatment of HIV and Sickle Cell Disease.
- Global Gene Therapy Initiative (GGTI)secondaryCaring Cross is a founding member of GGTI, a working group holding weekly meetings to discuss affordability and access of gene therapies globally. Provides knowledge transfer on technology and access issues, strategizes partnerships to improve access in low-and middle-income countries.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Caring Cross competitors and assessment
Company assessmentDirect peers
- Cellectis: Clinical-stage gene-editing company developing CAR-T cell therapies (UCART) using TALEN-based genome editing. Comparable as a CAR-T platform developer with active programs in leukemia/lymphoma, similar to Caring Cross's TriCAR-T multi-targeting approach.
- bluebird bio: Gene therapy company commercializing Lyfgenia for sickle cell disease and beti-cel for beta-thalassemia. Directly competes with Caring Cross in SCD/BT gene therapy, though at commercial >$2M price points rather than the affordable-access positioning.
- Allogene Therapeutics: Clinical-stage CAR-T company developing allogeneic ("off-the-shelf") CAR-T therapies for hematologic malignancies and solid tumors. Operates in the same CAR-T competitive arena as Caring Cross with overlapping indications in leukemia and lymphoma.
- Tmunity Therapeutics: University of Pennsylvania spin-out developing CAR-T cell therapies for cancer and other diseases. Most directly comparable to Caring Cross's TriCAR-T program given its academic-origin CAR-T focus, though operating as a private venture-backed company.
- Adaptimmune: Cell therapy company developing engineered TCR therapies for solid tumors and hematologic malignancies. Comparable as a cell therapy developer targeting blood cancers with engineered immune cell platforms.
Emerging players
- CRISPR Therapeutics: Co-developed Casgevy (exa-cel), the first FDA-approved CRISPR-based therapy for sickle cell disease and beta-thalassemia with Vertex. Overlaps with Caring Cross's SCD/BT stem cell gene therapy program but uses ex vivo CRISPR editing rather than lentiviral delivery.
Broad incumbents
- Novartis: Commercializer of Kymriah, the first FDA-approved CAR-T therapy (using the lentiviral vector originally developed by Caring Cross's co-founder). Broad incumbent in commercial CAR-T and a historical anchor reference point for the field.
- Vertex Pharmaceuticals: Through its partnership with CRISPR Therapeutics, commercializes Casgevy for sickle cell disease and beta-thalassemia, directly competing in the same indications Caring Cross targets via lower-cost lentiviral gene therapy.
- Gilead Sciences (Kite Pharma): Through Kite Pharma, commercializes Yescarta and Tecartus CAR-T therapies for lymphoma and ALL. Represents the established commercial CAR-T landscape Caring Cross aims to disrupt via point-of-care manufacturing cost reduction.
- Bristol-Myers Squibb: Markets Breyanzi and Abecma CAR-T therapies for lymphoma and multiple myeloma through the Celgene/Juno acquisition. Represents commercial CAR-T competition Caring Cross's TriCAR-T is positioned against in hematologic malignancies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Caring Cross social profiles
Digital presenceCaring Cross financial estimates
Financial estimateRevenue estimate
Valuation estimate
Caring Cross leadership team
Management profileNumber of profiles
Profiles2 records
Caring Cross subsidiaries and ownership
Company hierarchySubsidiaries1 record
Caring Cross funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Caring Cross M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Caring Cross
What does Caring Cross do?
Caring Cross is a 501(c)(3) nonprofit that develops CAR-T cell therapies and stem cell gene therapies for leukemia, lymphoma, HIV, sickle cell disease, and beta-thalassemia. The organization creates enabling technologies, including the proprietary T-isopure reagent and novel lentiviral vector manufacturing processes, and transfers these to partner Academic Medical Centers, government health agencies, and hospitals globally to enable decentralized, point-of-care manufacturing that reduces therapy costs from over $350,000 to approximately $35,000 per dose.
Is Caring Cross a public or private company?
Caring Cross is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Caring Cross founded?
Caring Cross was founded in 2012. It employs 11 to 50 people.
Where is Caring Cross based?
Caring Cross is headquartered in Gaithersburg, United States, in the North America region.
How does Caring Cross make money?
Four revenue lines are on record. Government Grants and Funding is the primary driver. The others are technology Transfer Agreements, corporate Partnership Services and donations and Charitable Contributions.
Who are Caring Cross's main competitors?
Direct peers on record are Cellectis, bluebird bio, Allogene Therapeutics, Tmunity Therapeutics and Adaptimmune. CRISPR Therapeutics is listed as an emerging player. Broad incumbents are Novartis, Vertex Pharmaceuticals, Gilead Sciences (Kite Pharma) and Bristol-Myers Squibb.
Does Caring Cross have an API?
No public API is recorded for Caring Cross.